{"id":"https://openalex.org/W7225737276","doi":"https://doi.org/10.25251/w1k3dx35","title":"Switching to Upadacitinib Monotherapy Was Associated With Minimal or No Flares Following Inadequate Response to Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis","display_name":"Switching to Upadacitinib Monotherapy Was Associated With Minimal or No Flares Following Inadequate Response to Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225737276","doi":"https://doi.org/10.25251/w1k3dx35"},"language":"en","primary_location":{"id":"doi:10.25251/w1k3dx35","doi":"https://doi.org/10.25251/w1k3dx35","is_oa":true,"landing_page_url":"https://doi.org/10.25251/w1k3dx35","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.25251/w1k3dx35","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011094833","display_name":"Matthew Zirwas","orcid":"https://orcid.org/0000-0002-8380-8114","observed_orcids":["https://orcid.org/0000-0002-8380-8114"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew J. Zirwas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006365271","display_name":"Diego Ruiz Dasilva","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Diego Ruiz Dasilva","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102966570","display_name":"Mona Shahriari","orcid":"https://orcid.org/0000-0002-1191-7557","observed_orcids":["https://orcid.org/0000-0002-1191-7557"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mona Shahriari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081439498","display_name":"Ayman A. Grada","orcid":"https://orcid.org/0000-0002-5321-0584","observed_orcids":["https://orcid.org/0000-0002-5321-0584"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ayman Grada","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5128645052","display_name":"Michael Lane","orcid":"https://orcid.org/0009-0006-4161-1467","observed_orcids":["https://orcid.org/0009-0006-4161-1467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael Lane","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032393407","display_name":"Brian Calimlim","orcid":"https://orcid.org/0000-0002-6463-6433","observed_orcids":["https://orcid.org/0000-0002-6463-6433"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian Calimlim","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005385912","display_name":"Meerat Oza","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meerat Oza","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5020785070","display_name":"Christopher G. Bunick","orcid":"https://orcid.org/0000-0002-4011-8308","observed_orcids":["https://orcid.org/0000-0002-4011-8308"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher G. Bunick","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"10","issue":"6","first_page":"s845","last_page":"s845"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9225999712944031},{"id":"https://openalex.org/C2780699399","wikidata":"https://www.wikidata.org/wiki/Q20708049","display_name":"Eczema Area and Severity Index","level":3,"score":0.8230999708175659},{"id":"https://openalex.org/C2779824493","wikidata":"https://www.wikidata.org/wiki/Q5315925","display_name":"Dupilumab","level":3,"score":0.7297000288963318},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.7050999999046326},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5372999906539917},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.4839000105857849},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46540001034736633},{"id":"https://openalex.org/C2781464078","wikidata":"https://www.wikidata.org/wiki/Q7685898","display_name":"Target lesion","level":4,"score":0.4219000041484833},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.4104999899864197},{"id":"https://openalex.org/C2781156865","wikidata":"https://www.wikidata.org/wiki/Q827023","display_name":"Lesion","level":2,"score":0.359499990940094},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.31949999928474426},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3093999922275543},{"id":"https://openalex.org/C205545832","wikidata":"https://www.wikidata.org/wiki/Q17156455","display_name":"Young adult","level":2,"score":0.289000004529953},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.2806999981403351},{"id":"https://openalex.org/C2988168687","wikidata":"https://www.wikidata.org/wiki/Q949302","display_name":"Skin lesion","level":2,"score":0.273499995470047},{"id":"https://openalex.org/C2780648854","wikidata":"https://www.wikidata.org/wiki/Q2745824","display_name":"Immunopathology","level":2,"score":0.26420000195503235},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.25279998779296875}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.25251/w1k3dx35","doi":"https://doi.org/10.25251/w1k3dx35","is_oa":true,"landing_page_url":"https://doi.org/10.25251/w1k3dx35","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.25251/w1k3dx35","doi":"https://doi.org/10.25251/w1k3dx35","is_oa":true,"landing_page_url":"https://doi.org/10.25251/w1k3dx35","pdf_url":null,"source":{"id":"https://openalex.org/S4210210594","display_name":"SKIN The Journal of Cutaneous Medicine","issn_l":"2574-1624","issn":["2574-1624"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","poland-20"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"SKIN The Journal of Cutaneous Medicine","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":2,"referenced_works":["https://openalex.org/W2118630839","https://openalex.org/W3189956257"],"related_works":[],"abstract_inverted_index":{"Patients":[0],"with":[1,33,111,133,167,182,192,324,349,361,387],"moderate-to-severe":[2,112],"atopic":[3],"dermatitis":[4],"(AD)":[5],"who":[6,39,55,114,198],"have":[7],"an":[8,183,350],"inadequate":[9,34,102,134,184,351],"response":[10,35,59,69,103,135,185,352],"to":[11,18,36,41,60,81,99,104,118,139,155,163,170,189,353,356,402],"biologic":[12],"therapy":[13],"may":[14,62,77,382],"benefit":[15],"from":[16,116,144,244,400],"switching":[17,98,263,355],"a":[19,57,223,231,254],"different":[20],"treatment":[21],"class.":[22],"In":[23,129],"the":[24,87,122,245,398],"LEVEL":[25,123,130,289,315,339,375],"UP":[26,29,124,127,290,316,320,340,376],"and":[27,50,94,125,150,197,209,230,276,283,291,295,341,367,377],"HEADS":[28,126,179,301,319,345,378],"studies,":[30],"most":[31],"patients":[32,54,110,132,181,252,323,337,348,388],"dupilumab":[37],"(DUPI)":[38],"switched":[40,115,162],"upadacitinib":[42],"(UPA)":[43],"achieved":[44],"clinically":[45,90,217],"meaningful":[46,91],"improvements":[47],"in":[48,121,147,227,235,288,300,314,333,338,344,374],"skin":[49,92,309,364,392],"itch":[51,95,210,330,369,395],"outcomes.":[52],"However,":[53],"experience":[56],"partial":[58,68],"DUPI":[61,117,156,193,401],"be":[63],"concerned":[64,389],"about":[65,390],"losing":[66],"their":[67],"or":[70,318,394],"experiencing":[71,253],"worsening":[72,391],"symptoms":[73],"after":[74,97,262,306],"discontinuation,":[75],"which":[76],"make":[78],"them":[79],"reluctant":[80],"switch":[82,272],"treatments.":[83],"This":[84,106],"analysis":[85,108],"assessed":[86],"occurrence":[88],"of":[89,247,251,268,336],"lesions":[93,393],"flares":[96,211,311,331,366,370,396],"UPA":[100,119,164,171,201,357],"following":[101],"DUPI.":[105],"post-hoc":[107],"included":[109],"AD":[113],"monotherapy":[120,358],"studies.":[128],"UP,":[131,180],"(defined":[136,186],"as":[137,187,222],"failure":[138,188],"achieve":[140,190],"\u2265":[141,224,232],"75%":[142],"improvement":[143],"baseline":[145],"severity":[146],"Eczema":[148],"Area":[149],"Severity":[151],"Index":[152],"score":[153,229],"[EASI75])":[154],"300":[157],"mg":[158,173,203],"at":[159,194,256,328],"Week":[160,195],"16":[161,260,304,372],"15":[165],"mg,":[166],"dose":[168],"escalation":[169],"30":[172,202],"based":[174],"on":[175],"clinical":[176],"response.":[177],"For":[178],"EASI75)":[191],"24":[196],"then":[199],"received":[200],"thereafter":[204],"were":[205,212,264,279,312],"analyzed.":[206],"Skin":[207],"lesion":[208,310,365],"defined":[213],"using":[214,266],"validated":[215],"minimal":[216],"important":[218],"difference":[219],"(MCID)":[220],"thresholds":[221],"6.6-point":[225],"increase":[226,234],"EASI":[228,275],"4-point":[233],"Worst":[236],"Pruritus":[237],"Numerical":[238],"Rating":[239],"Scale":[240],"(WP-NRS)":[241],"score,":[242],"respectively,":[243,287,299],"time":[246],"switching.":[248],"The":[249],"proportions":[250],"flare":[255],"any":[257],"assessment":[258],"through":[259,371],"weeks":[261,305,373],"evaluated":[265],"analyses":[267],"observed-case":[269],"data.":[270],"At":[271],"baseline,":[273],"mean":[274],"WP-NRS":[277,325],"scores":[278],"13.5":[280],"(SD,":[281,285,293,297],"7.7)":[282],"3.9":[284],"2.3),":[286],"11.8":[292],"4.6)":[294],"4.1":[296],"2.7),":[298],"UP.":[302,346,379],"Through":[303],"switching,":[307],"no":[308,362],"observed":[313,363],"(0/201)":[317],"(0/27).":[321],"Among":[322,347],"\u2264":[326],"6":[327],"switch,":[329],"occurred":[332],"3.6%":[334],"(5/139)":[335],"4.8%":[342],"(1/21)":[343],"DUPI,":[354],"was":[359],"associated":[360],"infrequent":[368],"These":[380],"findings":[381],"help":[383],"inform":[384],"treatment-switch":[385],"discussions":[386],"during":[397],"transition":[399],"UPA.":[403]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}